Can I read Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results on EtoBox?

Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results by Adam M. Brufsky; Linda D. Bosserman; Richard R. Caradonna; Barbara B. Haley; C. Michael Jones; Halle C.F. Moore; Lixian Jin; Ghulam M. Warsi; Solveig G. Ericson; Edith A. Perez is a Medicine article available to read on EtoBox.

What is Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results about?

Background: Postmenopausal women with breast cancer receiving adjuvant aromatase inhibitors (AIs) are at risk for accelerated bone loss and subsequent fractures. The ongoing Zometa-Femara Adjuvant Synergy Trial (Z-FAST) is evaluating the efficacy and safety of zoledronic acid in preventing such bone loss. Patients and Methods: In this multicenter study, postmenopausal women with early hormone receptor-positive breast cancer receiving adjuvant letrozole were randomized to receive up-front or delayed-start zoledronic acid (ZA; 4 mg intravenously every 6 months) for 5 years. Delayed-start ZA was administered if the lumbar spine (LS) or total hip (TH) T score fell below -2.0 or a nontraumatic fracture occurred. The primary endpoint was to compare the change from baseline in LS bone mineral density (BMD) between groups at month 12; secondary endpoints, measured at other predetermined timepoints, included comparing changes in TH BMD, LS BMD, and markers of bone turnover, fracture incidence, and time to disease recurrence. Herein, we report the results of the 36-month interim analysis. Results: Overall, 301 patients were randomized to each group. At month 36, the absolute difference in me

Who reads Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results?

Author

Adam M. Brufsky; Linda D. Bosserman; Richard R. Caradonna; Barbara B. Haley; C. Michael Jones; Halle C.F. Moore; Lixian Jin; Ghulam M. Warsi; Solveig G. Ericson; Edith A. Perez

Publisher

Elsevier BV

Published

2009

Language

EN

Field

Medicine (Health Sciences)